Comparison of features after 3 years in the groups with and without baseline eosinophilia
| Features | Eosinophils ≥500/mm3 N=26 | Eosinophils <500/mm3 N=778 | p Value |
|---|---|---|---|
| DAS28, mean (SD) | 3.2 (1.2) | 2.9 (1.4) | 0.17 |
| Patient VAS activity score, mean (SD) | 43.6 (32.6) | 28.4 (25.9) | 0.05 |
| Physician VAS activity score, mean (SD) | 24.0 (23.0) | 19.2 (19.8) | 0.32 |
| Morning stiffness intensity, mean (SD) | 36.0 (29.7) | 21.7 (23.3) | 0.05 |
| HAQ score, mean (SD) | 0.9 (0.7) | 0.5 (0.6) | 0.004 |
| CRP (mg/L), mean (SD) | 12.3 (19.5) | 6.6 (11.0) | 0.95 |
| Rate of erosion progression during year 1, mean (SD) | 3.6 (4.0) | 3.0 (4.6) | 0.83 |
| Rate of erosion progression between year 1 and year 3, mean (SD) | 2.5 (3.2) | 2.6 (4.2) | 0.41 |
| Corticosteroids, n (%) | 7/18 (38.9) | 229/606 (37.8) | 0.92 |
| DMARD, n (%) | 18/19 (94.7) | 476/669 (71.1) | 0.02 |
| Methotrexate, n (%) | 13/19 (68.4) | 370/673 (55.0) | 0.24 |
| Methotrexate dosage (mg/week), mean (SD) | 14.6 (3.5) | 13.3 (3.9) | 0.22 |
| Biological agent | 2/26 (7.7%) | 89/778 (11.4%) | 0.76 |
Bold typeface indicates p≤0.05.
CRP, C reactive protein; DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; VAS, visual analogue scale.